In the European Union only 1 in 7 eligible people is screened for colorectal cancer.
As a consequence, 60% of CRC cases are diagnosed when the cancer has already spread regionally or to distant organs and treatment becomes more challenging.
Epi proColon 2.0 CE is a blood test and offers an acceptable alternative to conventional screening methods. When diagnosed early, CRC is highly treatable.
Early detection can save lives!